drug therapy, combination

M1 macrophages induce PD-L1^hi cell-led collective invasion in HPV-positive head and neck squamous cell carcinoma via TNF-α/CDK4/UPS14
Jiashun Wu, Xin Pang, Xiao Yang, Mei Zhang, Bingjun Chen, Huayang Fan, Haofan Wang, Xianghua Yu, Yaling Tang, Xinhua Liang

Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e007670; DOI: 10.1136/jitc-2023-007670
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
Elizabeth Gray, Michelle Ulrich, Angela Epp, Patrick Younan, Disha Sahetya, Kelly Hensley, Sean Allred, Li-Ya Huang, Julie Hahn, Kristen Gahnberg, Piper M Treuting, Esther S Trueblood, John J Gosink, Robert Thurman, Serena Wo, Kellie Spahr, Evgenia Jane Haass, Katie Snead, Dannah Miller, Mary Padilla, Alyson J Smith, Chris Frantz, Jason P Schrum, Natalya Nazarenko, Shyra J Gardai

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007572; DOI: 10.1136/jitc-2023-007572
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
Paul Koller, Natalia Baran, Karine Harutyunyan, Antonio Cavazos, Saradhi Mallampati, Renee L Chin, Zhou Jiang, Xian Sun, Heng-Huan Lee, Jennifer L Hsu, Patrick Williams, Xuelin Huang, Michael A Curran, Mien-Chie Hung, Marina Konopleva

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e006619; DOI: 10.1136/jitc-2022-006619
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
Mehmet Akce, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L Shaib, Christina Wu, Olatunji B Alese, Maria Diab, Gregory B Lesinski, Bassel F El-Rayes

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007235; DOI: 10.1136/jitc-2023-007235
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
Sophia Frentzas, Steven Kao, Rang Gao, Hao Zheng, Ahsan Rizwan, Nageshwar Budha, Luz de la Hoz Pedroza, Wei Tan, Tarek Meniawy

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e005829; DOI: 10.1136/jitc-2022-005829
MCT4 blockade increases the efficacy of immune checkpoint blockade
Nathalie Babl, Sonja-Maria Decking, Florian Voll, Michael Althammer, Ada Sala-Hojman, Roberta Ferretti, Clarissa Korf, Christian Schmidl, Lisa Schmidleithner, Benedikt Nerb, Carina Matos, Gudrun E Koehl, Peter Siska, Christina Bruss, Fabian Kellermeier, Katja Dettmer, Peter J Oefner, Marvin Wichland, Ines Ugele, Christopher Bohr, Wolfgang Herr, Shivapriya Ramaswamy, Timo Heinrich, Christian Herhaus, Marina Kreutz, Kathrin Renner

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007349; DOI: 10.1136/jitc-2023-007349
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
Yu Fu, Bin Yang, Yaoyuan Cui, Xingyuan Hu, Xi Li, Funian Lu, Tianyu Qin, Li Zhang, Zhe Hu, Ensong Guo, Junpeng Fan, Rourou Xiao, Wenting Li, Xu Qin, Dianxing Hu, Wenju Peng, Jingbo Liu, Beibei Wang, Gordon B Mills, Gang Chen, Chaoyang Sun

Journal for ImmunoTherapy of Cancer Apr 2023, 11 (4) e006070; DOI: 10.1136/jitc-2022-006070
Response to 'Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC' by Yang et al
Kun Li, Yunfei Qin, Linsen Ye

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006648; DOI: 10.1136/jitc-2022-006648
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
Liya Ding, Qiwei Wang, Antons Martincuks, Michael J Kearns, Tao Jiang, Ziying Lin, Xin Cheng, Changli Qian, Shaozhen Xie, Hye-Jung Kim, Inga-Maria Launonen, Anniina Färkkilä, Thomas M Roberts, Gordon J Freeman, Joyce F Liu, Panagiotis A Konstantinopoulos, Ursula Matulonis, Hua Yu, Jean J Zhao

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e005627; DOI: 10.1136/jitc-2022-005627
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P Brown, David Goldstein

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e006136; DOI: 10.1136/jitc-2022-006136

Main menu

drug therapy, combination

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

drug therapy, combination

Pages